Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Moderate-to-severe Papulopustular Rosacea
NCT06532136Phase 2Withdrawn
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deucravacitinib in papulopustular rosacea, sponsored by Icahn School of Medicine at Mount Sinai. Planned start Nov 2024; status: withdrawn.
02
Drugs
deucravacitinib
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT06532136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532136.